Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Update on General Meeting

8 Feb 2022 09:34

RNS Number : 0204B
Sensyne Health PLC
08 February 2022
 

 

 

Sensyne Health plc

("Sensyne" or the "Company")

 

Update on General Meeting

 

Confirmed cases of COVID-19 mean that General Meeting will be held as a closed meeting

 

Oxford, U.K. 8 February 2022: Sensyne Health plc (LSE:SENS) today announces that due to a number of confirmed COVID-19 cases, the Company's General Meeting to be held at 2.00 p.m. on Friday, 11 February 2022 (the "General Meeting") will now be held as a closed meeting, with the minimum number of members legally required to be present to form a quorum in accordance with the Company's articles of association. Shareholders will not be permitted to attend in person and are therefore advised not to travel to the General Meeting. The Company is taking these precautionary measures to safeguard its shareholders', stakeholders' and employees' health and make the General Meeting as safe and efficient as possible.

 

Shareholders are encouraged to submit their votes by proxy in advance and to appoint the Chair of the meeting as their proxy (rather than their own choice of person), with voting instructions, to ensure their vote is counted. Completed forms of proxy must be returned so as to be received by the Company's Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA by no later than 2.00 p.m. on 9 February 2022, as set out in the Notice of General Meeting contained within the Circular sent to shareholders on 26 January 2022. The Circular is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Shareholders' attention is again drawn to the importance of voting at the General Meeting.

 

A video link for virtual attendance is being made available to provide shareholders with the opportunity to listen to the General Meeting and to have their questions answered. If you would like to join the video conference, please contact CSCSensynehealth@consilium-comms.com by close of business on Wednesday, 9 February 2022.

 

 

 

-ENDS-

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

Contact details:

Sensyne Health

 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 

 

Liberum (Joint Broker)

Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications

Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290

SternIR

Julie Seidel

Julie.seidel@sternir.com

 +1 (212) 362 1200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGFIFVAFLITIIF
Date   Source Headline
3rd Nov 20213:00 pmBUSForm 8.3 - SENS LN
3rd Nov 20212:10 pmRNSForm 8.3 - Sensyne Health plc
3rd Nov 20211:54 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 20211:10 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 202112:58 pmGNWInvesco Ltd.: Form 8 (OPD) - Sensyne Health PLC
3rd Nov 202112:08 pmRNSHolding(s) in Company
3rd Nov 202112:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
3rd Nov 20219:51 amRNSForm 8.5 (EPT/RI)
3rd Nov 20218:23 amRNSForm 8.3 - Sensyne Health Plc
2nd Nov 20213:02 pmGNWForm 8.3 - Octopus Investments - Sensyne Health plc
2nd Nov 20217:00 amRNSStrategic update, FSP triggered by potential MBO
29th Oct 20215:04 pmRNSResults of Annual General Meeting
21st Oct 20217:00 amRNSMagnifEye European regulatory certification
15th Oct 20217:00 amRNSSensyne and OMNY Health Sign Teaming Agreement
6th Oct 20217:00 amRNSHoldings in Company
6th Oct 20217:00 amRNSAnnual Report and Accounts
4th Oct 20212:05 pmRNSSecond Price Monitoring Extn
4th Oct 20212:00 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSSensyne Health 2021 Financial Results
24th Sep 20217:00 amRNSNotice of Preliminary Results
9th Sep 20217:00 amRNSLaunch of SENSIGHT data analytics platform
2nd Sep 20217:00 amRNSSensyne & GOSH partner in child disease research
19th Aug 20217:00 amRNSSensyne SRA With Sentara Healthcare
10th Aug 20217:00 amRNSSensyne announces AI drug discovery project
2nd Aug 20217:01 amRNSBoard Change
2nd Aug 20217:00 amRNSSensyne dataset reaches 60m patients
22nd Jul 20217:00 amRNSAppointment of Chief Scientific Officer
19th Jul 20217:00 amRNSSensyne Health Provides Strategic Update
18th Jun 20217:00 amRNSNED Appointment
17th Jun 20213:02 pmRNSHolding(s) in Company
1st Jun 20217:00 amRNSMagnifEye Production Contract with UK DHSC
28th May 20212:24 pmRNSShare Option Award
27th May 20217:00 amRNSTrading Update
25th May 20211:13 pmRNSHolding(s) in Company
24th May 20217:00 amRNSSRA with Colorado Center for Personalized Medicine
21st May 20219:14 amRNSPharmaceutical collaboration
21st May 20217:00 amRNSSensyne signs SRA with St. Luke’s
7th May 202111:12 amRNSHolding(s) in Company
7th May 20217:00 amRNSMagnifEye Gains MHRA Approval
6th May 20217:00 amRNSValue Creation Plan Award
30th Apr 20217:00 amRNSSensyne SRA with Royal Devon and Exeter NHS Trust
16th Apr 20217:00 amRNSIssue of Shares and Total Voting Rights
12th Mar 20217:00 amRNSAgreement with the UK DHSC
1st Mar 20217:00 amRNSSYNE-COV Achieves UK Regulatory Approval
1st Mar 20217:00 amRNSBoard Changes
10th Feb 20212:06 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
9th Feb 20217:48 amRNSSensyne licenses MagnifEye technology to Excalibur
5th Feb 20212:57 pmRNSHoldings in Company
5th Feb 20212:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.